Quality-by-Design (QbD): An integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space development.
The aim of this work was to develop an integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and design space development. A dynamic co-precipitation process by gradually introducing water to the ternary system of naproxen-Eudragit L100-alcohol was monitored at real-time in situ via Lasentec FBRM and PVM. 3D map of count-time-chord length revealed three distinguishable process stages: incubation, transition, and steady-state. The effects of high risk process variables (slurry temperature, stirring rate, and water addition rate) on both derived co-precipitation process rates and final chord-length-distribution were evaluated systematically using a 3(3) full factorial design. Critical process variables were identified via ANOVA for both transition and steady state. General linear models (GLM) were then used for parameter estimation for each critical variable. Clear trends about effects of each critical variable during transition and steady state were found by GLM and were interpreted using fundamental process principles and Nyvlt's transfer model. Neural network models were able to link process variables with response variables at transition and steady state with R(2) of 0.88-0.98. PVM images evidenced nucleation and crystal growth. Contour plots illustrated design space via critical process variables' ranges. It demonstrated the utility of integrated PAT approach for QbD development.
Division of Product Quality Research (DPQR, HFD-940), OTR/OPS/CDER/FDA, The FDA White Oak Campus, Life Science Building 64, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States. Huiquan.Wu@fda.hhs.gov
Huiquan
H
Wu
Maury
M
White
Mansoor A
MA
Khan
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry; D055598:Chemical Phenomena; D011232:Chemical Precipitation; D004339:Drug Compounding / Q000379:methods*; D004867:Equipment Design / Q000379:methods*; D005079:Excipients / Q000737:chemistry*; D009288:Naproxen / Q000737:chemistry*; D011109:Polymethacrylic Acids / Q000737:chemistry; D058996:Quality Improvement; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005079:Excipients; D011109:Polymethacrylic Acids; C038300:methylmethacrylate-methacrylic acid copolymer; D009288:Naproxen